Market Place
Sourcing Support
Scilex Company Announces Signing of $50 Million Convertible Financing
07 Oct 2024 //
GLOBENEWSWIRE
Oramed Pharmaceuticals Restructures Scilex Holding Company Debt
07 Oct 2024 //
PR NEWSWIRE
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
26 Jun 2024 //
PR NEWSWIRE
Oramed Letter to Shareholders
26 Jun 2024 //
PR NEWSWIRE
Oramed, HTIT Create Joint Venture to Advance Oral Drug Delivery
02 Aug 2023 //
PR NEWSWIRE
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
18 May 2023 //
PR NEWSWIRE
Oramed Announces that its Chinese Partner, HTIT, has Completed a Ph 3 Oral
15 May 2023 //
PR NEWSWIRE
Oramed to review strategic alternatives, clouding path forward for oral insulin
10 Feb 2023 //
ENDPTS
Oramed Pharmaceuticals Issues Shareholder Update
09 Feb 2023 //
PR NEWSWIRE
Oramed ditches oral insulin for diabetes after Phase III study failure
13 Jan 2023 //
FIERCE BIOTECH
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 and Insulin
04 Jan 2023 //
PR NEWSWIRE
Oramed Letter to Shareholders – December
21 Dec 2022 //
PRESS RELEASE
Oramed Letter to Shareholders
21 Dec 2022 //
PR NEWSWIRE
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal
29 Nov 2022 //
PRNEWSWIRE
MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea
18 Nov 2022 //
PRNEWSWIRE
Oramed Announces Positive Safety Data from Phase 2 Clinical Trial of ORMD-0801
17 Nov 2022 //
PRNEWSWIRE
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin
14 Nov 2022 //
MARKETSCREENER
Oramed Reports Third Quarter 2022 Financial Results
10 Nov 2022 //
PRNEWSWIRE
Oramed to Host Webinar Detailed Safety and Efficacy Data Pha2 Trial ORMD-0801
09 Nov 2022 //
PRNEWSWIRE
Oravax announces positive initial data from Phase I Covid-19 vaccine trial
10 Oct 2022 //
CLINICALTRIALSARENA
Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
07 Oct 2022 //
PRNEWSWIRE
Oramed Reports Results from Phase 2 NASH Trial with its ORMD-0801
13 Sep 2022 //
PRNEWSWIRE
Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 Sep 2022 //
PRNEWSWIRE
Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
26 Jul 2022 //
PRNEWSWIRE
Why Oramed Pharmaceuticals Stock Is On Fire Today
12 Jul 2022 //
FOOL
Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference
11 Jul 2022 //
PRNEWSWIRE
Oramed Letter to Shareholders
07 Jul 2022 //
PRNEWSWIRE
Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board
01 Jun 2022 //
PRNEWSWIRE
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin
24 May 2022 //
PRNEWSWIRE
Oramed to Present at H.C. Wainwright Global Investment Conference
18 May 2022 //
PRNEWSWIRE
Oramed Granted NASH Patent in Europe
05 Apr 2022 //
PRNEWSWIRE
Oramed Appoints Yadin Rozov to its Board of Directors
04 Apr 2022 //
PRNEWSWIRE
Oramed`s Diabetes Market Survey Shows ORMD-0801 Oral Insulin Candidate
29 Mar 2022 //
PRNEWSWIRE
Oramed to Host Key Opinion Leader Webinar for Oral Insulin in Type 2 Diabetes
22 Mar 2022 //
PRNEWSWIRE
Oramed Completes Patient Enrollment in P 2 Oral Insulin NASH Trial
16 Mar 2022 //
PRNEWSWIRE
Oramed to Present at Barclays Global Healthcare Conference
10 Mar 2022 //
PRNEWSWIRE
Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement
29 Dec 2021 //
PRNEWSWIRE
Oravax Begins Enrollment in Phase 1 Oral COVID-19 Vaccine Trial
14 Dec 2021 //
PRNEWSWIRE
Oramed Pharmaceuticals Appoints Chief Legal Officer
08 Dec 2021 //
PRNEWSWIRE
Premas, Oravax to Test Their Triple Antigen Oral Vaccine Against Omicron
01 Dec 2021 //
BUSINESSWIRE
Oramed to Join MSCI USA Small Cap Index
24 Nov 2021 //
PRNEWSWIRE
Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study
23 Nov 2021 //
PRNEWSWIRE
Oravax, Genomma Lab Announce Joint Venture for Oral COVID-19 Vaccine
18 Nov 2021 //
BUSINESSWIRE
Oramed Announces Closing of $50M Registered Direct Offering of Common Stock
08 Nov 2021 //
PRNEWSWIRE
Oramed Announces $50 Million Registered Direct Offering of Common Stock
03 Nov 2021 //
PRNEWSWIRE
Oravax`s Oral COVID-19 Vaccine Receives Approval in S.Africa for Phase 1 Trial
29 Oct 2021 //
PRNEWSWIRE
Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
23 Sep 2021 //
PRNEWSWIRE
Oramed`s Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
15 Sep 2021 //
PRNEWSWIRE
Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep 2021 //
PRNEWSWIRE
Oramed Reaches 25% Enrollment in Its Two Concurrent Phase 3 Oral Insulin Trials
24 Aug 2021 //
PRNEWSWIRE
Oramed Publishes Oral Insulin Study in Diabetes, Obesity, and Metabolism
16 Aug 2021 //
PR NEWSWIRE
MyMD Pharmaceuticals to Commence Clinical Trials for Oral COVID-19 Vaccine
10 Aug 2021 //
BUSINESSWIRE
Oramed to Present at Canaccord Genuity`s 41st Annual Growth Conference
09 Aug 2021 //
PRNEWSWIRE
Oramed to Present at Canaccord Genuity`s 41st Annual Growth Conference
09 Aug 2021 //
PRNEWSWIRE
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine
05 Aug 2021 //
PRNEWSWIRE
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine
05 Aug 2021 //
PRNEWSWIRE
Oramed Pharmaceuticals Appoints Chief Commercial Officer
29 Jul 2021 //
PRNEWSWIRE
Oramed Update on Oravax,Oral Vaccine Maker Gets IRB Approval for Clinical Trial
21 Jul 2021 //
PRNEWSWIRE
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
22 Jun 2021 //
PRNEWSWIRE
Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study
08 Jun 2021 //
BEZINGA
